Compare FLYW & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLYW | URGN |
|---|---|---|
| Founded | 2009 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 2021 | 2016 |
| Metric | FLYW | URGN |
|---|---|---|
| Price | $17.60 | $46.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 7 |
| Target Price | $16.21 | ★ $29.29 |
| AVG Volume (30 Days) | ★ 2.2M | 795.1K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 450.00 | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $623,025,000.00 | $1,128,000.00 |
| Revenue This Year | $19.68 | $129.09 |
| Revenue Next Year | $15.25 | $70.96 |
| P/E Ratio | $580.50 | ★ N/A |
| Revenue Growth | ★ 26.59 | N/A |
| 52 Week Low | $10.55 | $15.86 |
| 52 Week High | $18.98 | $48.19 |
| Indicator | FLYW | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 53.52 | 67.57 |
| Support Level | $17.29 | $18.23 |
| Resistance Level | $18.05 | N/A |
| Average True Range (ATR) | 0.64 | 2.39 |
| MACD | 0.07 | 0.35 |
| Stochastic Oscillator | 59.94 | 86.58 |
Flywire Corp provides a secure payment platform, offering its clients a streamlined process to receive reconciled domestic and international payments more cost-effectively and efficiently. The company's solutions are built on three core elements, namely a payments platform, a proprietary payment network, and vertical-specific software backed by its deep industry expertise. Geographically, the majority of revenue is from the Americas.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.